Digital Health is a fast growing area of the healthcare ecosystem. It covers a wide variety of areas including big data, artificial intelligence, sensors, wearables, apps, software, diagnostics, digital therapeutics, telemedicine to name but a few. As we move ever closer towards healthcare solutions and integrated care, the convergence of technology with the pharmaceutical industry is well under way.
Leslie Galloway, Chairman of EMIG commented “Following a high level of interest from our members, I am pleased to announce that EMIG has now officially launched a Digital Health Group to ensure that our members are engaged in and will be a part of the healthcare of tomorrow.”
The group is being Chaired by Darren Spevick of Eventum Partners, with the aims of
- raising the profile and awareness of the opportunities that digital health and health technology represents for EMIG Members – SME pharmaceutical companies.
- collaborating with other relevant organisations such as Medcity, digitalhealth.london, AHSN’s, The NHS, The Office for Life Sciences, patient organisations and so on, to create an environment where all interested parties can come together so that we can all realise the benefits of digital health.
For further information please contact Leslie Galloway or Darren Spevick on:
Leslie Galloway – email@example.com
Darren Spevick – firstname.lastname@example.org
About EMIG (www.emig.org.uk)
EMIG is the research based biopharmaceutical trade association that represents the interests of over 200 companies and organisations based in the UK. Our members range from start-ups, whose prime focus is often research and development (R&D), to highly developed businesses delivering essential products to patients and the NHS. They are commonly, but not exclusively, small to medium-sized enterprises (SMEs). Less than 20% of our members are represented by other trade bodies.
The UK life sciences industry provides vital medicines to patients, is at the forefront of medical innovation and is a significant contributor to the UK economy. SMEs constitute approximately 90% of the total number of biopharmaceutical companies and it is estimated that 80% of innovation is derived from these small companies. EMIG member companies employ approximately 20,000 people in the UK and have a combined annual turnover of £4bn.
About Eventum Partners (www.eventumpartners.com)
Eventum Partners are an outcome focused executive recruitment consultant that specialise in making senior interim and permanent appointments for healthcare technology, healthcare services and life science companies.